Lasmiditan is associated with greater odds of achieving pain freedom from migraine attacks compared with placebo.
A pooled analysis evaluated reductions in migraine and headache days among patients with chronic migraine and comorbid depression in 2 placebo-controlled, phase 3 trials of fremanezumab.
Migraine has a considerable impact on women’s pregnancy plans, with about 20% avoiding pregnancy due to migraine.
Internationally, more than 3 in 10 patients with multiple sclerosis with migraine.
The therapeutic gain for 2-hour pain freedom is an important outcome to assess efficacy of acute migraine therapies.
Patients with vestibular migraine are more likely to have occipital headaches than those without vestibular symptoms.
Compared to patients with migraine without vestibular symptoms, those with vestibular migraine are more likely to experience occipital headaches.
The heterogeneous expression of headache associated with COVID-19 indicates various underlying pathophysiological mechanisms.
The ADVANCE study included 910 adults who experienced 4 to 14 migraines per month.
Lasmiditan efficacy after a single dose was similar for the various subgroups of patients defined by baseline demographics and migraine attack characteristics.